Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Aug 21 2024

Full Issue

Zepbound Appears To Dramatically Lower Risk Of Developing Diabetes

Eli Lilly says that its Phase 3 trial data show that people with prediabetes who took the company's obesity drug had a 93% lower risk of progressing to diabetes as opposed to the people in the study who took the placebo.

Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing the benefits of long-term use of the blockbuster therapy. In a Phase 3 trial that lasted over three years, people with pre-diabetes taking Zepbound had a 93% lower risk of progressing to diabetes compared with people on placebo, Lilly said Tuesday. The company did not report absolute risk rates. (Chen, 8/20)

Related news about weight loss drugs —

A new study that found evidence of a higher rate of suicidal thoughts among patients taking Novo Nordisk A/S’s popular weight-loss and diabetes drugs is adding to a debate among doctors about the drugs’ safety. The study published Tuesday in JAMA Network Open is the first to mine the World Health Organization’s global database of suspected drug side effects for reports of suicidal thinking in patients who have taken the drugs. (Kresge, 8/20)

Eli Lilly & Co. is using its runaway success in obesity as a bridge into another lucrative area of medicine: immunology. This fall, the company will begin recruiting for trials to test its popular weight-loss shot Zepbound with psoriasis drug Taltz to see if the combination boosts effectiveness, Chief Scientific Officer Daniel Skovronsky said. The Indianapolis-based drugmaker is also exploring combination studies with Zepbound in inflammatory bowel disease, another immune disorder. (Muller, 8/20)

Employers are bracing for the largest surge in healthcare costs in more than a decade as pharmacy spending is expected to continue accelerating next year. Growing demand for pricey medications, including glucagon-like peptide-1 agonists, cancer treatments, and cell and gene therapies, has employers budgeting for a 7.8% increase in healthcare costs in 2025, according to the Business Group on Health’s annual survey, published Tuesday. (Berryman, 8/20)

Other news about diabetes —

For sausage, salami and steak lovers, the news has not been good. Scientists have been consistently finding links between red and processed meat consumption and heart disease, some types of cancer and earlier death. And now, two recent studies have added to the growing body of evidence that a meat-heavy diet may increase the risk of Type 2 diabetes. (Callahan, 8/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ